Authors
Creative Bioarray
Summary
Creative Bioarray offers a broad range of well-characterized xenograft, patient-derived xenograft (PDX), syngeneic tumor models as well as genetically engineered mouse models (GEMMs). Combining these models with appropriate biomarkers, including flow cytometry and imaging, our portfolio allows our partners to select the most appropriate study design and screening method to identify promising compounds and optimize lead candidates.
Introduction
Cancer research is highly dependent on representative and reliable model systems. However, cancer is not a single molecule-defined tumor, but rather a heterogeneous and highly variable complex of different individual diseases, making research on cancer very difficult and expensive, which at the same time explains the enormous resources required.
The models used by cancer research are changing constantly and extending to all stages of drug discovery including target identification, lead structure optimization, biomarker analysis, tolerability, toxicity, and individual patient prediction. Currently, choosing the most appropriate model to best reflect the given tumor entity is one of the major challenges that cancer researchers are facing.
Creative Bioarray is committed to providing you with the most innovative preclinical models to delineate the underlying mechanism of disease and enable you to choose the most promising candidates. Our mission is to help accelerate next generation targeted cancer therapies to benefit patients in a safe, effective and affordable manner.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 242
- Comments 0